News | March 01, 2024
Briefs: Eugia Pharma Specialities and Eugia SEZ
Eugia Pharma Specialities restarts production at terminally sterilized product lines
Eugia Pharma Specialities restarts production at terminally sterilized product lines
_in_Mizushima,_Japan_256_384.jpg)
Contributing to lower risk of potentially carcinogenic nitrosamine impurities in pharmaceuticals
BHL will undertake the development and supply of these molecules
Varenicline is indicated for smoking cessation in adults
Suven Pharmaceuticals’ API and forumulations facilities complete USFDA inspection successfully
The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU
IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
Subscribe To Our Newsletter & Stay Updated
